Cargando…

Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)

SIMPLE SUMMARY: Hepatoblastoma is the most common malignant liver tumor in children. Small cell undifferentiated histology and low alpha-fetoprotein have been previously reported as factors associated with poor prognosis. It is important to exclude rhabdoid tumors (a rare pediatric liver tumor that...

Descripción completa

Detalles Bibliográficos
Autores principales: Trobaugh-Lotrario, Angela D., Maibach, Rudolf, Aronson, Daniel C., Rangaswami, Arun, Häberle, Beate, O’Neill, Allison F., Schmid, Irene, Ansari, Marc, Hishiki, Tomoro, Ranganathan, Sarangarajan, Alaggio, Rita, de Krijger, Ronald R., Tanaka, Yukichi, Cho, Soo-Jin, Vokuhl, Christian, Maxwell, Rebecca, Krailo, Mark, Hiyama, Eiso, Czauderna, Piotr, Finegold, Milton, Feusner, James H., Malogolowkin, Marcio H., Meyers, Rebecka L., Lopez-Terrada, Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857147/
https://www.ncbi.nlm.nih.gov/pubmed/36672416
http://dx.doi.org/10.3390/cancers15020467
_version_ 1784873801975070720
author Trobaugh-Lotrario, Angela D.
Maibach, Rudolf
Aronson, Daniel C.
Rangaswami, Arun
Häberle, Beate
O’Neill, Allison F.
Schmid, Irene
Ansari, Marc
Hishiki, Tomoro
Ranganathan, Sarangarajan
Alaggio, Rita
de Krijger, Ronald R.
Tanaka, Yukichi
Cho, Soo-Jin
Vokuhl, Christian
Maxwell, Rebecca
Krailo, Mark
Hiyama, Eiso
Czauderna, Piotr
Finegold, Milton
Feusner, James H.
Malogolowkin, Marcio H.
Meyers, Rebecka L.
Lopez-Terrada, Dolores
author_facet Trobaugh-Lotrario, Angela D.
Maibach, Rudolf
Aronson, Daniel C.
Rangaswami, Arun
Häberle, Beate
O’Neill, Allison F.
Schmid, Irene
Ansari, Marc
Hishiki, Tomoro
Ranganathan, Sarangarajan
Alaggio, Rita
de Krijger, Ronald R.
Tanaka, Yukichi
Cho, Soo-Jin
Vokuhl, Christian
Maxwell, Rebecca
Krailo, Mark
Hiyama, Eiso
Czauderna, Piotr
Finegold, Milton
Feusner, James H.
Malogolowkin, Marcio H.
Meyers, Rebecka L.
Lopez-Terrada, Dolores
author_sort Trobaugh-Lotrario, Angela D.
collection PubMed
description SIMPLE SUMMARY: Hepatoblastoma is the most common malignant liver tumor in children. Small cell undifferentiated histology and low alpha-fetoprotein have been previously reported as factors associated with poor prognosis. It is important to exclude rhabdoid tumors (a rare pediatric liver tumor that is difficult to cure) in patients diagnosed with hepatoblastoma with alpha-fetoprotein levels less than 100 ng/mL and in patients with hepatoblastoma with small cell undifferentiated histology since the treatment for these patients is very different. When rhabdoid tumors are correctly diagnosed with testing for loss of SMARCB1, neither hepatoblastoma with small cell undifferentiated component nor alpha-fetoprotein less than 100 ng/mL confer poor prognosis. ABSTRACT: Small cell undifferentiated (SCU) histology and alpha-fetoprotein (AFP) levels below 100 ng/mL have been reported as poor prognostic factors in hepatoblastoma (HB); subsequent studies reported SMARCB1 mutations in some SCU HBs confirming the diagnosis of rhabdoid tumor. The Children’s Hepatic tumors International Collaboration (CHIC) database was queried for patients with HB who had AFP levels less than 100 ng/mL at diagnosis or were historically diagnosed as SCU HBs. Seventy-three of 1605 patients in the CHIC database were originally identified as SCU HB, HB with SCU component, or HB with low AFP levels. Upon retrospective review, they were re-classified as rhabdoid tumors (n = 11), HB with SCU component (n = 41), and HB with low AFP (n = 14). Seven were excluded for erroneously low AFP levels. Overall survival was 0% for patients with rhabdoid tumors, 76% for patients with HB with SCU component, and 64% for patients with HB with AFP less than 100 ng/mL. Patients with HB with SCU component or low AFP should be assessed for SMARCB1 mutations and, if confirmed, treated as rhabdoid tumors. When rhabdoid tumors are excluded, the presence of SCU component and low AFP at diagnosis were not associated with poor prognosis in patients diagnosed with HB.
format Online
Article
Text
id pubmed-9857147
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98571472023-01-21 Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC) Trobaugh-Lotrario, Angela D. Maibach, Rudolf Aronson, Daniel C. Rangaswami, Arun Häberle, Beate O’Neill, Allison F. Schmid, Irene Ansari, Marc Hishiki, Tomoro Ranganathan, Sarangarajan Alaggio, Rita de Krijger, Ronald R. Tanaka, Yukichi Cho, Soo-Jin Vokuhl, Christian Maxwell, Rebecca Krailo, Mark Hiyama, Eiso Czauderna, Piotr Finegold, Milton Feusner, James H. Malogolowkin, Marcio H. Meyers, Rebecka L. Lopez-Terrada, Dolores Cancers (Basel) Article SIMPLE SUMMARY: Hepatoblastoma is the most common malignant liver tumor in children. Small cell undifferentiated histology and low alpha-fetoprotein have been previously reported as factors associated with poor prognosis. It is important to exclude rhabdoid tumors (a rare pediatric liver tumor that is difficult to cure) in patients diagnosed with hepatoblastoma with alpha-fetoprotein levels less than 100 ng/mL and in patients with hepatoblastoma with small cell undifferentiated histology since the treatment for these patients is very different. When rhabdoid tumors are correctly diagnosed with testing for loss of SMARCB1, neither hepatoblastoma with small cell undifferentiated component nor alpha-fetoprotein less than 100 ng/mL confer poor prognosis. ABSTRACT: Small cell undifferentiated (SCU) histology and alpha-fetoprotein (AFP) levels below 100 ng/mL have been reported as poor prognostic factors in hepatoblastoma (HB); subsequent studies reported SMARCB1 mutations in some SCU HBs confirming the diagnosis of rhabdoid tumor. The Children’s Hepatic tumors International Collaboration (CHIC) database was queried for patients with HB who had AFP levels less than 100 ng/mL at diagnosis or were historically diagnosed as SCU HBs. Seventy-three of 1605 patients in the CHIC database were originally identified as SCU HB, HB with SCU component, or HB with low AFP levels. Upon retrospective review, they were re-classified as rhabdoid tumors (n = 11), HB with SCU component (n = 41), and HB with low AFP (n = 14). Seven were excluded for erroneously low AFP levels. Overall survival was 0% for patients with rhabdoid tumors, 76% for patients with HB with SCU component, and 64% for patients with HB with AFP less than 100 ng/mL. Patients with HB with SCU component or low AFP should be assessed for SMARCB1 mutations and, if confirmed, treated as rhabdoid tumors. When rhabdoid tumors are excluded, the presence of SCU component and low AFP at diagnosis were not associated with poor prognosis in patients diagnosed with HB. MDPI 2023-01-11 /pmc/articles/PMC9857147/ /pubmed/36672416 http://dx.doi.org/10.3390/cancers15020467 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Trobaugh-Lotrario, Angela D.
Maibach, Rudolf
Aronson, Daniel C.
Rangaswami, Arun
Häberle, Beate
O’Neill, Allison F.
Schmid, Irene
Ansari, Marc
Hishiki, Tomoro
Ranganathan, Sarangarajan
Alaggio, Rita
de Krijger, Ronald R.
Tanaka, Yukichi
Cho, Soo-Jin
Vokuhl, Christian
Maxwell, Rebecca
Krailo, Mark
Hiyama, Eiso
Czauderna, Piotr
Finegold, Milton
Feusner, James H.
Malogolowkin, Marcio H.
Meyers, Rebecka L.
Lopez-Terrada, Dolores
Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)
title Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)
title_full Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)
title_fullStr Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)
title_full_unstemmed Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)
title_short Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)
title_sort outcomes of patients treated for hepatoblastoma with low alpha-fetoprotein and/or small cell undifferentiated histology: a report from the children’s hepatic tumors international collaboration (chic)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857147/
https://www.ncbi.nlm.nih.gov/pubmed/36672416
http://dx.doi.org/10.3390/cancers15020467
work_keys_str_mv AT trobaughlotrarioangelad outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT maibachrudolf outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT aronsondanielc outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT rangaswamiarun outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT haberlebeate outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT oneillallisonf outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT schmidirene outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT ansarimarc outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT hishikitomoro outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT ranganathansarangarajan outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT alaggiorita outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT dekrijgerronaldr outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT tanakayukichi outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT chosoojin outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT vokuhlchristian outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT maxwellrebecca outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT krailomark outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT hiyamaeiso outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT czaudernapiotr outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT finegoldmilton outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT feusnerjamesh outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT malogolowkinmarcioh outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT meyersrebeckal outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic
AT lopezterradadolores outcomesofpatientstreatedforhepatoblastomawithlowalphafetoproteinandorsmallcellundifferentiatedhistologyareportfromthechildrenshepatictumorsinternationalcollaborationchic